J
Jorge Lima
Researcher at University of Porto
Publications - 73
Citations - 4706
Jorge Lima is an academic researcher from University of Porto. The author has contributed to research in topics: Cancer & Thyroid cancer. The author has an hindex of 27, co-authored 63 publications receiving 4198 citations. Previous affiliations of Jorge Lima include Institute of Molecular Pathology and Immunology of the University of Porto.
Papers
More filters
Journal ArticleDOI
Frequency of TERT promoter mutations in human cancers.
João Vinagre,Ana Margarida Almeida,Ana Margarida Almeida,Helena Pópulo,Rui Batista,Joana Lyra,Joana Lyra,Vasco Pinto,Vasco Pinto,Ricardo Marques Coelho,Ricardo Marques Coelho,Ricardo Celestino,Hugo Prazeres,Luís Lima,Miguel Melo,Adriana Gaspar da Rocha,Adriana Gaspar da Rocha,Ana Preto,Ana Preto,Patrícia Castro,Lígia Castro,Fernando Pardal,José Manuel Lopes,José Manuel Lopes,Lúcio Lara Santos,Rui Manuel Reis,José Cameselle-Teijeiro,Manuel Sobrinho-Simões,Manuel Sobrinho-Simões,Jorge Lima,Jorge Lima,Valdemar Máximo,Valdemar Máximo,Paula Soares,Paula Soares +34 more
TL;DR: The results show that TERT promoter mutations are relatively frequent in specific types of human cancers, where they lead to enhanced expression of telomerase.
Journal ArticleDOI
BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC
Paula Soares,Vítor Trovisco,Ana Rocha,Jorge Lima,Patrícia Castro,Ana Preto,Valdemar Máximo,Tiago Botelho,Raquel Seruca,Manuel Sobrinho-Simões +9 more
TL;DR: The results suggest that BRAFV599E mutation is frequent in the etiopathogenesis of PTC, and appears to be an alternative event to RET/PTC rearrangement rather than to RAS mutations, which are rare in PTC.
Journal ArticleDOI
TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.
Miguel Melo,Miguel Melo,Adriana Gaspar da Rocha,Adriana Gaspar da Rocha,João Vinagre,João Vinagre,Rui Batista,Joana Peixoto,Catarina Tavares,Catarina Tavares,Ricardo Celestino,Ana Margarida Almeida,Ana Margarida Almeida,Alves Salgado Catarina Miguel,Catarina Eloy,Patrícia Castro,Hugo Prazeres,Jorge Lima,Teresina Amaro,Cláudia Lobo,Maria Joao Martins,Margarida Moura,Branca M. Cavaco,Valeriano Leite,José Cameselle-Teijeiro,Francisco Carrilho,Manuela Carvalheiro,Valdemar Máximo,Valdemar Máximo,Manuel Sobrinho-Simões,Manuel Sobrinho-Simões,Paula Soares,Paula Soares +32 more
TL;DR: TERT promoter mutations are an indicator of clinically aggressive tumors, being correlated with worse outcome and disease-specific mortality in DTC and, notably, in PTC, where they have an independent prognostic value.
Journal ArticleDOI
Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness
Vítor Trovisco,Paula Soares,Paula Soares,Ana Preto,Inês Vieira de Castro,Jorge Lima,Patrícia Castro,Valdemar Máximo,Tiago Botelho,Severina Moreira,Ana M. Meireles,J.F Magalhaes,Alexander Abrosimov,José Cameselle-Teijeiro,Manuel Sobrinho-Simões,Manuel Sobrinho-Simões +15 more
TL;DR: The BRAF (BRAFV600E) mutated PTC did not exhibit signs of higher aggressiveness and were in fact less often multicentric than PTC without the mutation.
Journal ArticleDOI
Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hürthle cell tumors.
TL;DR: The mtDNA common deletion (CD) was evaluated by semiquantitative polymerase chain reaction as mentioned in this paper, and the mtDNA variants and mtDNA somatic mutations of complex I and complex IV genes seem to be involved in thyroid tumorigenesis.